| Literature DB >> 28969648 |
Sara Darbandi1, Mahsa Darbandi1, Hamid Reza Khorram Khorshid2, Mohammad Reza Sadeghi1, Ashok Agarwal3, Pallav Sengupta4, Safaa Al-Hasani5, Mohammad Mehdi Akhondi6.
Abstract
BACKGROUND: Ooplasmic transfer (OT) technique or cytoplasmic transfer is an emerging technique with relative success, having a significant status in assisted reproduction. This technique had effectively paved the way to about 30 healthy births worldwide. Though OT has long been invented, proper evaluation of the efficacy and risks associated with this critical technique has not been explored properly until today. This review thereby put emphasis upon the applications, efficacy and adverse effects of OT techniques in human. MAIN BODY: Available reports published between January 1982 and August 2017 has been reviewed and the impact of OT on assisted reproduction was evaluated. The results consisted of an update on the efficacy and concerns of OT, the debate on mitochondrial heteroplasmy, apoptosis, and risk of genetic and epigenetic alteration. SHORTEntities:
Keywords: Apoptosis; Epigenetic modifications; Genetic modifications; Mitochondria; Ooplasmic transfer
Mesh:
Year: 2017 PMID: 28969648 PMCID: PMC5625659 DOI: 10.1186/s12958-017-0292-z
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Comparison of embryonic development potential after MI and MII ooplasmic transfer (OT) in mammalian sample
| Supplier information | Survival information | Pregnancy information | Explanation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Species | D | R | OT (%) | Fertilized (%) | 2-cell (%) | 4-cell (%) | 6-cell (%) | 8-cell (%) | Blastocyst (%) | ET (%) | pregnancy | Birth | |
| Monkey [ | MII | MI | 42 | 23 (54.8%) | – | – | – | – | – | – | 4 (9.5%) | 3 (7.1%) | – |
| Sham MI | 43 | 26 (60.5%) | – | – | – | – | – | – | 0 | 0 | – | ||
| Control MI | 37 | 30 (81%) | – | – | – | – | – | – | 0 | 0 | – | ||
| MII | MII | 22 | 22 (100%) | – | – | – | – | – | – | 4 (18%) | 4 (18%) | – | |
| Sham MII | 18 | 18 (100%) | – | – | – | – | – | – | 3 (16.7%) | 3 (16.7%) | – | ||
| Control MII | 24 | 24 (100%) | – | – | – | – | – | – | 6 (25%) | 4 (16%) | |||
| Human [ | MII | MII | 14(100) | 9 (64.3%) | 8 (57.1%) | 8 (57.1%) | 8 (57.1%) | 8 (57.1%) | 4 (28.6%) | 4 (28.6%) | 1 (7.1%) | 1 (7.1%) | amniocyte nDNA and mtDNA fingerprinting |
| Human [ | MII | MII | 22 fused | 15 (68.2%) | – | – | – | 10 (46.4%) | – | 3 (13.6%) | 0 | 0 | amniocyte nDNA and mtDNA fingerprinting |
| MII | MII | 48 | 38 (79.17%) | – | – | – | 8(16.7) | – | 5 (10.4%) | 3 (6.3%) | 1 (2.1%) | amniocyte nDNA and mtDNA fingerprinting | |
| Control MII | 17 | 9 (52.9%) | – | – | – | 0 | – | – | – | – | – | ||
| Human [ | Cryo_MII | MII | 37 | 26 (70.3%) | – | – | – | – | – | 17 (45.9%) | 2 | 2 (5%) | – |
| Human [ | 3PN | MII | 62 | 44 (80%) | 39 (63%) | – | 39 (63%) | – | – | 39 (63%) | 4 (6.4%) | 4 | amniocentesis and karyotyping |
| Human [ | MII | MII | 26 | – | – | – | – | – | – | – | – | 2 (7.7%) | Confocal microscopy and mtDNA fingerprinting |
| Human [ | MII | MII | 8 | 6 (75%) | 6 (75%) | 5 (62.5%) | 4 (50%) | 2 (25%) | – | 4 (50%) | 2 (25%) | 2 (25%) | – |
| MII Control | 4 | 3 (75%) | 3 (75%) | 1 (25%) | – | – | – | – | – | – | – | ||
Donor: “D”. Recipient: “R”
Comparison of embryonic development potential after PN, 1-cell and 2-cell ooplasmic transfer (OT) in mammalian sample
| Supplier information | Survival information | Pregnancy information | Explanation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Species | D | R | OT (%) | Fertilized (%) | 2-cell (%) | 4-cell (%) | 6-cell (%) | 8-cell (%) | Blastocyst (%) | ET (%) | pregnancy | delivery | |
| Mouse [ | F1,1-cell | MF1,1-cell | 58 (55%) | 106 | 46 (43.8%) | 11 (10.4%) | – | 9 (8.5%) | 0 | ||||
| MF1,1-cell control | 84 | 84 (95.5%) | 39 (44.3%) | – | 38 (43.1%) | 35 (39.8%) | |||||||
| Mouse [ | F1,2-cell | MF1,1-cell | 42 (58%) | 73 | 42 (58%) | 31 (43%) | – | 30 (41.7%) | 17 (23.6%) | ||||
| MF1,1-cell control | 92 | 92 (100%) | 13 (14.1%) | – | 1 (1.09%) | 1 (1.09%) | |||||||
| Mouse [ | F1,2-cell | F1.1-cell | 18 (75%) | 24 | 18 (75%) | 2 (0.03%) | – | 9 (8.5%) | 0 | ||||
| F1,1-cell control | 73 | 73 (100%) | 72 (98.6%) | – | 68 (93.1%) | 59 (80.8%) | |||||||
| Mouse [ | F1,2-cell,G1 | F1.1-cell,G1 | – | 267 | – | – | – | – | 72 (27%) | ||||
| F1,2-cell,G1 | F1.1-cell,G2 | – | 664 | – | – | – | – | 73 (11%) | |||||
| F1,2-cell,S | F1.1-cell,S | – | 800 | – | – | – | – | 40 (5%) | |||||
| F1,2-cell,G2 | F1.1-cell,G2 | – | 111 | – | – | – | – | 50 (45%) | |||||
| F1.1-cell, | – | 315 | – | – | – | – | 221 (70%) | ||||||
| F1,2-cell,G1 | MF1.1-cell,G1 | – | 29 | – | – | – | – | 12 (42%) | |||||
| F1,2-cell,G1 | MF1.1-cell,S | – | 800 | – | – | – | – | 8 (0%) | |||||
| F1,2-cell,G1 | MF1.1-cell,G2 | – | 128 | – | – | – | – | 28 (22%) | |||||
| F1,2-cell,S | MF1.1-cell,G2 | – | 1300 | – | – | – | – | 13 (0%) | |||||
| F1,2-cell,G2 | MF1.1-cell,G2 | – | 1067 | – | – | – | – | 32 (3%) | |||||
| MF1.1-cell, | – | 67,500 | – | – | – | – | 270 (0.4%) | ||||||
| F1,2-cell,G1 | CD1.1-cell,G2 | – | 40 | – | – | – | – | 20 (50%) | |||||
| F1,2-cell,S | CD1.1-cell,G2 | – | 2600 | – | – | – | – | 26 (0%) | |||||
| F1,2-cell,G2 | CD1.1-cell,G2 | – | 89 | – | – | – | – | 46 (52%) | |||||
| CD1,2-cell,G2 | CD1.1-cell,G2 | – | 2523 | – | – | – | – | 40 (1.5%) | |||||
| CD1.1-cell, | – | 3350 | – | – | – | – | 134 (4%) | ||||||
| Mouse [ | PN | PN | 224 | – | – | – | – | 193 (86.2%) | 106 (47.3%) | 66 (29.5%) | 24 (10.7%) | ||
| MII | PN | 419 | – | – | – | – | 306 (73.03%) | 134 (32%) | 91 (21.7%) | 71 (17%) | |||
| GV | PN | 224 | – | – | – | – | 109 (48.7%) | 40 (17.9%) | 11 (4.9%) | 5 (2.2%) | |||
| PN control | 1114 | – | – | – | – | 1020 (91.6%) | 246 (22.1%) | 135 (12.1%) | 99 (8.91%) | ||||